Head-To-Head Survey: Perspective Therapeutics (NYSE:CATX) versus Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ)

Perspective Therapeutics (NYSE:CATX) and Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, risk and institutional ownership.

Institutional and Insider Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. 3.5% of Perspective Therapeutics shares are owned by insiders. Comparatively, 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Perspective Therapeutics and Health Sciences Acquisitions Co. 2, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	1	8	0	2.89
Health Sciences Acquisitions Co. 2	0	0	0	0	0.00

Perspective Therapeutics presently has a consensus price target of $15.14, suggesting a potential upside of 374.70%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, equities analysts plainly believe Perspective Therapeutics is more favorable than Health Sciences Acquisitions Co. 2.

Earnings & Valuation

This table compares Perspective Therapeutics and Health Sciences Acquisitions Co. 2″s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Perspective Therapeutics	$1.43 million	150.77	-$46.51 million	N/A	N/A
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A

Health Sciences Acquisitions Co. 2 has lower revenue, but higher earnings than Perspective Therapeutics.

Profitability

This table compares Perspective Therapeutics and Health Sciences Acquisitions Co. 2’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-4,096.66%	-27.40%	-23.16%
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%

Volatility & Risk

Perspective Therapeutics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Health Sciences Acquisitions Co. 2 has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500.

Summary

Health Sciences Acquisitions Co. 2 beats Perspective Therapeutics on 6 of the 11 factors compared between the two stocks.

About Perspective Therapeutics

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.